NASDAQ:TVGN Semper Paratus Acquisition (TVGN) Stock Price, News & Analysis $1.06 -0.01 (-0.93%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+1.42%) As of 07/25/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Semper Paratus Acquisition Stock (NASDAQ:TVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TVGN alerts:Sign Up Key Stats Today's Range$1.04▼$1.0950-Day Range$1.06▼$1.4352-Week Range$0.26▼$3.09Volume476,583 shsAverage Volume621,931 shsMarket Capitalization$194.92 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. Read More Semper Paratus Acquisition Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreTVGN MarketRank™: Semper Paratus Acquisition scored higher than 85% of companies evaluated by MarketBeat, and ranked 162nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSemper Paratus Acquisition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSemper Paratus Acquisition has only been the subject of 1 research reports in the past 90 days.Read more about Semper Paratus Acquisition's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Semper Paratus Acquisition's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of Semper Paratus Acquisition has been sold short.Short Interest Ratio / Days to CoverSemper Paratus Acquisition has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Semper Paratus Acquisition has recently decreased by 97.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSemper Paratus Acquisition does not currently pay a dividend.Dividend GrowthSemper Paratus Acquisition does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.10% of the float of Semper Paratus Acquisition has been sold short.Short Interest Ratio / Days to CoverSemper Paratus Acquisition has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Semper Paratus Acquisition has recently decreased by 97.26%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment1.28 News SentimentSemper Paratus Acquisition has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Semper Paratus Acquisition this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for TVGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Semper Paratus Acquisition insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,768,993.00 in company stock.Percentage Held by Insiders73.24% of the stock of Semper Paratus Acquisition is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Semper Paratus Acquisition's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Semper Paratus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Stock News HeadlinesTevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active PeptidesJuly 18, 2025 | globenewswire.comTevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing FacilityJuly 17, 2025 | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 27 at 2:00 AM | Porter & Company (Ad)Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha LaunchJuly 16, 2025 | globenewswire.comTevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development CostsJuly 14, 2025 | globenewswire.comTevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate InnovationJuly 10, 2025 | globenewswire.comTevogen Bio Holdings Inc News (TVGN) - Investing.comJuly 8, 2025 | investing.comTevogen CEO Contributes to Build-Out and First-Year Operations of New HeadquartersJune 30, 2025 | globenewswire.comSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Semper Paratus Acquisition's stock was trading at $1.03 on January 1st, 2025. Since then, TVGN shares have increased by 2.9% and is now trading at $1.06. How do I buy shares of Semper Paratus Acquisition? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Semper Paratus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Semper Paratus Acquisition investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Today7/26/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Semper Paratus Acquisition$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+843.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.73 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-934.56% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-11.78Miscellaneous Outstanding Shares183,890,000Free Float49,210,000Market Cap$194.92 million OptionableN/A Beta-0.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:TVGN) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.